Changes in Beneficial Ownership · 4
Cellectar Biosciences, Inc.
CLRBNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
tm2620095-6_4seq1.xml
Filing details
- Report period
- 2026-07-07
- Issuer
- Cellectar Biosciences, Inc.
- Issuer CIK
- 0001279704
- Trading symbol
- CLRB
Reporting owner 1
- Name
- CARUSO JAMES V
- Reporting owner CIK
- 0001202770
- Relationship
- Director · Officer
- Officer title
- President & CEO
- Address
- C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy) | 3.14 | 2026-07-07[F1] | A · Form 4 | 250,000 | A | 0 | [F2] | 2036-05-28 | Common stock | 250,000 | 250,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- This option was contingently granted on May 28, 2026, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2026 Annual Meeting of Stockholders. Such stockholder approval was obtained on July 7, 2026.↩ 1
- F2
- This option shall vest over a period of three years from May 28, 2026, with 1/3 vesting on the first anniversary of May 28, 2026, and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of May 28, 2026↩ 1
Signature 1
- Signed
- /s/ Chad Kolean, attorney-in-fact for James V. Caruso
- Date
- 2026-07-08
Company context
We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. We believe that our PDC platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments, and we plan to develop PDCs both independently and through research and development collaborations.
Current securities
Recent company filings
- SCHEDULE 13G - filed by Caligan Partners LP regarding Cellectar Biosciences, Inc.Aug 14, 2026
- SCHEDULE 13G - filed by STEMPOINT CAPITAL LP regarding Cellectar Biosciences, Inc.Aug 14, 2026
- SCHEDULE 13G - filed by BALYASNY ASSET MANAGEMENT L.P. regarding Cellectar Biosciences, Inc.Aug 14, 2026
- SCHEDULE 13G - filed by Bleichroeder LP regarding Cellectar Biosciences, Inc.Aug 13, 2026
- Results of Operations and Financial ConditionAug 13, 2026